Spinal analgesic actions of kappa receptor agonists, U-50488H and spiradoline (U-62066) - PubMed (original) (raw)
. 1989 Oct;251(1):267-71.
Affiliations
- PMID: 2552077
Spinal analgesic actions of kappa receptor agonists, U-50488H and spiradoline (U-62066)
M F Piercey et al. J Pharmacol Exp Ther. 1989 Oct.
Abstract
Administered i.p. to mice, the selective kappa receptor agonists U-50488H and spiradoline (U-62066) were more potent on the tail-flick than on the hot-plate analgesic assay. Both were more potent after i.s. rather than i.c. administration, a result consistent with earlier demonstrations that tail-flick analgesia is generally dependent upon spinal mechanisms. Intraspinal U-50488H was not effective in elevating rat tail-flick latencies. Both drugs increased the thresholds for cat spinal cord nociceptive neurons to respond to a noxious heat stimulus. However, maximal responses of spinal cord neurons to nociceptive stimuli were not altered. It is concluded that although spinal cord sites may be critical to kappa receptor analgesic mechanisms, the effects are quite distinct from spinal cord effects observed previously with classical narcotic analgesics.
Similar articles
- A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
Wadenberg ML. Wadenberg ML. CNS Drug Rev. 2003 Summer;9(2):187-98. doi: 10.1111/j.1527-3458.2003.tb00248.x. CNS Drug Rev. 2003. PMID: 12847558 Free PMC article. Review. - Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.
Vonvoigtlander PF, Lewis RA. Vonvoigtlander PF, et al. J Pharmacol Exp Ther. 1988 Jul;246(1):259-62. J Pharmacol Exp Ther. 1988. PMID: 2839665 - Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ, Członkowski A, Lipkowski A, Herz A. Millan MJ, et al. J Pharmacol Exp Ther. 1989 Oct;251(1):342-50. J Pharmacol Exp Ther. 1989. PMID: 2571723 - Synergistic antinociceptive interactions among drugs administered to the spinal cord.
Solomon RE, Gebhart GF. Solomon RE, et al. Anesth Analg. 1994 Jun;78(6):1164-72. doi: 10.1213/00000539-199406000-00025. Anesth Analg. 1994. PMID: 8198277 Review. No abstract available.
Cited by
- Estrogens Suppress Spinal Endomorphin 2 Release in Female Rats in Phase with the Estrous Cycle.
Kumar A, Storman EM, Liu NJ, Gintzler AR. Kumar A, et al. Neuroendocrinology. 2015;102(1-2):33-43. doi: 10.1159/000430817. Epub 2015 Apr 29. Neuroendocrinology. 2015. PMID: 25925013 Free PMC article. - A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
Wadenberg ML. Wadenberg ML. CNS Drug Rev. 2003 Summer;9(2):187-98. doi: 10.1111/j.1527-3458.2003.tb00248.x. CNS Drug Rev. 2003. PMID: 12847558 Free PMC article. Review. - Estrogens as arbiters of sex-specific and reproductive cycle-dependent opioid analgesic mechanisms.
Gintzler AR, Storman EM, Liu NJ. Gintzler AR, et al. Vitam Horm. 2019;111:227-246. doi: 10.1016/bs.vh.2019.06.002. Epub 2019 Jul 2. Vitam Horm. 2019. PMID: 31421702 Free PMC article. - Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia.
Chakrabarti S, Liu NJ, Gintzler AR. Chakrabarti S, et al. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20115-9. doi: 10.1073/pnas.1009923107. Epub 2010 Nov 1. Proc Natl Acad Sci U S A. 2010. PMID: 21041644 Free PMC article. - Antinociceptive Effects of Kappa-Opioid Receptor Agonists.
Lazenka MF. Lazenka MF. Handb Exp Pharmacol. 2022;271:293-313. doi: 10.1007/164_2020_430. Handb Exp Pharmacol. 2022. PMID: 33387069 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous